Featured Post
NEWS FROM SWEDEN: First delivery of extemporaneous medicinal products manufactured using 3D technology
First delivery of extemporaneous medicinal products manufactured using 3D technology
Apotek Produktion och Laboratorier AB (APL), one of the largest manufacturers of compounded medicines and a leading Contract Development and Manufacturing Organization (CDMO) in Sweden, announces its first delivery of a compounded medicine produced by 3D-printing technology. APL applies 3D-printing technology within the concept ExtempoPrint.
We are excited to join #PediatRxCon34 from April 9th-12th
We are excited to participate in the #PediatRxCon34 in Portland from April 9th to 12th!
CurifyLabs on TV Again!
Our customer Johannes Wesling Klinikum in Minden was the topic of a television report, putting the light on the use of our Pharmaprinter at their hospital.
CurifyLabs is Honored to be Presenting at #APhA2025 in Nashville
CurifyLabs honored to be presenting at #APhA2025 in Nashville, March 21–24.
Revolutionizing pharmaceutical treatment with the help of new technologies - case iGalenici in Italy
Revolutionizing pharmaceutical treatment with the help of new technologies - case iGalenici in Italy
Live From Training the Helios Erfurt Pharmacy Team!
3D printed medicines Helios Erfurt Pharmacy automated compounding technology non-sterile
Press Release: Prinses Máxima Center Implements CurifyLabs' Compounding Technology to Advance Personalized Pediatric Treatments
Press Release: Prinses Máxima Center Implements CurifyLabs' Compounding Technology to Advance Personalized Pediatric Treatments
Interview with Dr. Florian Immekus, Pharmacy Director, Mühlenkreiskliniken, Germany
Interview with Dr. Florian Immekus, Pharmacy Director, Mühlenkreiskliniken, Minden, Germany
The future of the pharmacy profession depends on the integration of modern technology
Modern technology can address staffing shortages and burnout in the pharmacy profession, enhancing efficiency and patient care through automation, robotics, and virtual reality.